Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PAM | P19021 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | P2RY10 | O00398 | 2/20 | 0.43 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598488 | 1.00 | LMNA (0.50) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL598288 | 1.00 | LMNA (0.50) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL9665651 | 1.00 | LMNA (0.50) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL9664746 | 1.00 | LMNA (0.50) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL599360 | 1.00 | LMNA (0.50) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL28031745 | 0.98 | MAPT (0.49) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL29431881 | 0.98 | MAPT (0.49) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL3283798 | 0.98 | MAPT (0.47) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL598924 | 0.98 | MAPT (0.47) | LMNAMAPTDGKAALDH1A1PAM | |
| SCHEMBL15649495 | 0.87 | LMNA (0.53) | LMNAMAPTDGKAALDH1A1PAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117224420-B | Oil-soluble lip-rounding compound peptide and preparation method thereof | 南京斯拜科生物科技股份有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-117224420-A | Oil-soluble lip-rounding compound peptide and preparation method thereof | 南京斯拜科生物科技股份有限公司 | 2023-12-15 | — | — | CN | claimed |
| WO-2015111034-A1 | APPARATUS AND METHODS FOR SKIN TREATMENT, DRUG APPLICATION AND CREAM FORMULATION | AMIT NOAH (IL) | 2015-07-30 | — | — | WO | claimed |
| US-20260014066-A1 | Silk-Based Moisturizer Compositions and Methods Thereof | EVOLVED BY NATURE INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250387196-A1 | SEGMENTAL OSCILLATION TOOL AND LUBRICANT | FLORMAN MICHAEL J (US) | 2025-12-25 | — | — | US | disclosed |
| US-12447122-B2 | Silk-based moisturizer compositions and methods thereof | EVOLVED BY NATURE, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4587635-A2 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | Evolved by Nature, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230203-A1 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | EVOLVED BY NATURE, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2024059862-A9 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250049652-A1 | AQUEOUS DISPERSION AND COSMETIC | MIYOSHI KASEI, INC. (JP) | 2025-02-13 | — | — | US | disclosed |
| US-20250000750-A1 | COMPOSITIONS, GARMENTS COMPRISING SAME AND METHODS FOR MOISTURISING SKIN | QILTA LIMITED (IE) | 2025-01-02 | — | — | US | disclosed |
| WO-2011015758-A2 | USE OF ISOLEUCINE N-HEXADECANOYL AS A VOLUMIZING AND/OR PLUMPING AGENT FOR HUMAN SKIN | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2011-02-10 | — | — | WO | disclosed |
| US-20100240741-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LABORATORIES, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7754679-B2 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| WO-2010026325-A1 | USE OF AN N-ACYL AMINO ACID SELECTED FROM AMONG N-PALMITOYL ALANINE, N-PALMITOYL GLYCINE, N-PALMITOYL ISOLEUCINE, AND N-COCOYL ALANINE AS AN ACTIVE AGENT CONTROLLING THE PROPORTION OF BASAL KERATINOCYTES OF THE HUMAN SKIN EPIDERMIS AND EXPRESSING THE NUCLEAR FORM OF SURVIVING, AND ANTI-AGING COSMETIC COMPOSITION COMPRISING SAME | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010023390-A1 | USE OF AN N-ACYL AMINO ACID SELECTED FROM AMONG N-PALMITOYL ALANINE, N-PALMITOYL GLYCINE, AND N-PALMITOYL ISOLEUCINE AS A REGULATING ACTIVE AGENT OF THE GENETIC PROFILE OF SENESCENT REPLICATING FIBROBLASTS OF THE HUMAN SKIN DERMIS | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) | 2010-03-04 | — | — | WO | disclosed |
| EP-1948199-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX Laboratories Inc (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007058801-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | IDEXX LABORATORIES INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | IDEXX LABORATORIES INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240741-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF APTAMERS | PHOSPHO1, SGMS1, PCYT1A | LMNA 576/4885MAPT 1126/4885DGKA 1080/4885 |
| US-20250000750-A1 | COMPOSITIONS, GARMENTS COMPRISING SAME AND METHODS FOR MOISTURISING SKIN | CUTA, NOTUM, ATP6V0C | LMNA 2351/4885MAPT 3675/4885DGKA 230/4885 |
| US-20070111969-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | LMNA 576/4885MAPT 1126/4885DGKA 1080/4885 |
| US-20260014066-A1 | Silk-Based Moisturizer Compositions and Methods Thereof | CUTA, CD44, F12 | LMNA 673/4885MAPT 817/4885DGKA 2194/4885 |
| US-20250387196-A1 | SEGMENTAL OSCILLATION TOOL AND LUBRICANT | DVL1, DVL3, SHH | LMNA 3214/4885MAPT 4607/4885DGKA 517/4885 |
| US-20070110827-A1 | Pharmaceutical compositions for the administration of aptamers | PHOSPHO1, SGMS1, PCYT1A | LMNA 576/4885MAPT 1126/4885DGKA 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.